论文部分内容阅读
本文对乙型肝炎30例随机分为两组,观察组应用胸腺肽治疗20例,对照组应用健肝胶囊治疗10例,疗程6个月。结果:自觉症状与SGPT值较治疗前有改善,但与对照组比较无差异:特异性细胞免疫指标中灭活HBsAg疫苗皮试与对照组比较有显著差异,HBV各项血清学标记两组均无明显变化。表明胸腺肽作为免疫增强剂对乙型迁、慢性肝炎的治疗作用是有限的。治疗过程中无不良反应和副作用。
In this paper, 30 cases of hepatitis B were randomly divided into two groups, the observation group of thymosin treatment of 20 cases, the control group of 10 cases of Jiangan capsule treatment for 6 months. Results: There was no significant difference between the symptoms and the SGPT value before treatment, but there was no difference with the control group. There was a significant difference between the skin test of inactivated specific HBsAg vaccine and the control group. No significant changes. Thymosin as an immunostimulant shows that the role of migration of chronic hepatitis B, is limited. No adverse reactions and side effects during treatment.